

H.C. WAINWRIGHT HIRES EDWARD WHITE AS SENIOR BIOTECHNOLOGY ANALYST

NEW YORK, July 12, 2017 – H.C. Wainwright & Co., LLC (“HCW”) announced today that Edward P. White has joined the firm’s equity research group as Managing Director, Senior Biotechnology Analyst. At HCW, he will focus his research coverage on small to mid-cap life sciences companies.

Mr. White joins HCW from FBR & Company, where he was a Senior Biotech Equity Research Analyst. Prior to FBR, he worked in several healthcare equity research groups, including Deutsche Bank Securities and BMO Capital Markets. He also worked for six years as a Senior Buyside Healthcare Research Analyst at Mitsubishi UFJ Trust.

“We are excited to have Ed as a member of the biotechnology research team at HCW,” commented Mark Viklund, Chief Executive Officer of HCW. “With Ed’s addition, HCW now has 8 senior analysts covering the life sciences sector as we advance our goal of providing comprehensive coverage of companies across the complete market capitalization spectrum.

About H.C. Wainwright & Co., LLC

H.C. Wainwright & Co., LLC is an investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private growth companies across multiple sectors and regions. The H.C. Wainwright team has been the leader in the PIPE (private investment in public equity), RD (registered direct offering) and CMPO (Confidentially Marketed Public Offering) transaction markets. H.C. Wainwright was established in 1868 and is headquartered in New York City.